Generic and specialty pharmaceutical company Mylan Pharmaceuticals has introduced a portfolio of women's healthcare products in India, expanding its product base in the country.
Consisting of eight products initially, the portfolio is focused on hormones, pre- and post-natal nutrition and management of premenstrual syndrome (PMS).
Mylan CEO Heather Bresch said women's care being a high-growth therapeutic category in India provides the company with an opportunity to help satisfy unmet medical needs.
"More than 85% of women of childbearing age in India suffer from PMS, approximately one in five pregnancies in Indian women end in miscarriage, and it is estimated that the number of infertile couples in India is around 12 million.
"In addition to launching our innovative, high quality product portfolio, Mylan will help to strengthen the capabilities of health care providers in this area through training programs and workshops, working together with the medical community to address areas of concern in women's health and improve timely access to appropriate high quality treatment."
The company has launched a complete portfolio of antiretroviral products in India earlier and expects to continue to expand into new therapeutic categories along with field force expansion.
